Hydroxyapatite Active Pro Healing Clinical Trial Program (HApFIM)
Primary Purpose
Coronary Artery Disease
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Intravascular Coronary Stent
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Stent, Hydroxyapatite, Coronary Artery Stenosis, Angioplasty
Eligibility Criteria
Inclusion Criteria:
- Patient is 18 years old
- Patient is eligible for percutaneous coronary intervention (PCI)
- Patient is an acceptable candidate for CABG
- Clinical evidence of ischemic heart disease and/or a positive territorial functional study. Documented stable angina pectoris ((Canadian Cardiovascular Society (CCS) Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia
- The target lesion is a single de novo coronary artery lesion with 50 and 100% stenosis in one of the major epicardial territories (LAD, LCX or RCA). A second target lesion in another major epicardial vessel could be treated and this second lesion should fit with inclusion/exclusion criteria and will receive the same type of stent.
- The target lesion must be covered by one study stent preferably with a margin of at least 4mm on each side of the lesion
- The target lesion length should be ≤ 11 mm
- The target reference vessel diameter must be 3.0mm and 3.5mm
- Patient or the patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site
Exclusion Criteria:
- Female of childbearing potential
- Documented left ventricular ejection fraction (LVEF) 30%
- Evidence of an acute Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure, unless the CK and CK-MB enzymes are less than twice the Upper Normal Limit
- Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), heparin, Stainless Steel , contrast agent (that cannot be adequately pre-medicated) or drugs similar to hydroxyapatite
- A platelet count 100,000 cells/mm3 or 700,000 cells/mm3 or a WBC 3,000 cells/mm3
- Acute or chronic renal dysfunction (creatinine 2.0 mg/dl or 150µmol/L)
- Total occlusion (TIMI 0 or 1 (one))
- Target vessel has evidence of thrombus or is excessively tortuous that makes it unsuitable for proper stent delivery and deployment;
- Previous bare metal stenting (less than 1 year) anywhere within the target vessel
- Previous drug-eluting stenting anywhere within the target vessel;
- The target lesion requires treatment with a device other than PTCA prior to stent placement (e.g. but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.)
- Significant (50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off;
- Heavily calcified lesion and/or calcified lesion which cannot be successfully predilated
- Target lesion is located in or supplied by an arterial or venous bypass graft
- Ostial target lesion
- Target lesion involves a side branch 2.0mm in diameter with an ostial disease
- Patient is currently participating in an investigational drug or device study
- Within 30 days prior procedure patient has undergone a previous coronary interventional procedure of any kind
- Within 60 days post-procedure patient requires planned interventional treatment of any non-target vessel. Planned intervention of the target vessel after the index procedure is not allowed
- Stroke or transient ischemic attack within the prior 6 months
- Unprotected Left Main (LM) coronary artery disease (stenosis >50%)
- In the investigator's opinion patient has a co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
- Planned surgery within 6 months after index procedure
- Life expectancy less than 1 year
Sites / Locations
Outcomes
Primary Outcome Measures
In-stent late-loss at 4 and 12 months (as measured by QCA), defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiographic MLD
Secondary Outcome Measures
Full Information
NCT ID
NCT00474084
First Posted
May 15, 2007
Last Updated
May 15, 2007
Sponsor
BioSync Scientific Pvt. Ltd.
Collaborators
MIV Therapeutics Inc., Cardialysis BV
1. Study Identification
Unique Protocol Identification Number
NCT00474084
Brief Title
Hydroxyapatite Active Pro Healing Clinical Trial Program
Acronym
HApFIM
Official Title
First In Man Evaluation of the Vesta™ & VestaCOR™ (Hydroxy-Apetite Coated genX™) Stent for Treatment of de Novo Native Coronary Artery Lesion(s)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2007
Overall Recruitment Status
Unknown status
Study Start Date
July 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
BioSync Scientific Pvt. Ltd.
Collaborators
MIV Therapeutics Inc., Cardialysis BV
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this first feasibility study is to evaluate the performance of Vesta™ & VestaCOR™ (Hydroxy-Apetite coated GenX) stent in de novo native coronary artery lesions. This study will provide the longest follow-up experience available.
This is a randomized, double blind study conducted at three sites, two sites in India and one in The Netherlands. To be eligible, a patient will be required to have a de novo stenotic lesion of a length that could be covered by a single stent in a native coronary artery of diameter 3.0mm and 3.5mm. A total of at least 60 patients and a maximum of 70 patients will be treated with Vesta™ & VestaCOR™ stent. These patients will be randomized to either a smooth surface nanofilm coated stent (= VestaCOR™) (approx. 35 patients) or to a porous coated stent (= Vesta™) (approx. 35 patients).
All patients will be followed clinically at 30 days, 4 months, 9 months, 1, 2, 3, 4 and 5 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Stent, Hydroxyapatite, Coronary Artery Stenosis, Angioplasty
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Intravascular Coronary Stent
Primary Outcome Measure Information:
Title
In-stent late-loss at 4 and 12 months (as measured by QCA), defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiographic MLD
Time Frame
4 & 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is 18 years old
Patient is eligible for percutaneous coronary intervention (PCI)
Patient is an acceptable candidate for CABG
Clinical evidence of ischemic heart disease and/or a positive territorial functional study. Documented stable angina pectoris ((Canadian Cardiovascular Society (CCS) Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia
The target lesion is a single de novo coronary artery lesion with 50 and 100% stenosis in one of the major epicardial territories (LAD, LCX or RCA). A second target lesion in another major epicardial vessel could be treated and this second lesion should fit with inclusion/exclusion criteria and will receive the same type of stent.
The target lesion must be covered by one study stent preferably with a margin of at least 4mm on each side of the lesion
The target lesion length should be ≤ 11 mm
The target reference vessel diameter must be 3.0mm and 3.5mm
Patient or the patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site
Exclusion Criteria:
Female of childbearing potential
Documented left ventricular ejection fraction (LVEF) 30%
Evidence of an acute Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure, unless the CK and CK-MB enzymes are less than twice the Upper Normal Limit
Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), heparin, Stainless Steel , contrast agent (that cannot be adequately pre-medicated) or drugs similar to hydroxyapatite
A platelet count 100,000 cells/mm3 or 700,000 cells/mm3 or a WBC 3,000 cells/mm3
Acute or chronic renal dysfunction (creatinine 2.0 mg/dl or 150µmol/L)
Total occlusion (TIMI 0 or 1 (one))
Target vessel has evidence of thrombus or is excessively tortuous that makes it unsuitable for proper stent delivery and deployment;
Previous bare metal stenting (less than 1 year) anywhere within the target vessel
Previous drug-eluting stenting anywhere within the target vessel;
The target lesion requires treatment with a device other than PTCA prior to stent placement (e.g. but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.)
Significant (50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off;
Heavily calcified lesion and/or calcified lesion which cannot be successfully predilated
Target lesion is located in or supplied by an arterial or venous bypass graft
Ostial target lesion
Target lesion involves a side branch 2.0mm in diameter with an ostial disease
Patient is currently participating in an investigational drug or device study
Within 30 days prior procedure patient has undergone a previous coronary interventional procedure of any kind
Within 60 days post-procedure patient requires planned interventional treatment of any non-target vessel. Planned intervention of the target vessel after the index procedure is not allowed
Stroke or transient ischemic attack within the prior 6 months
Unprotected Left Main (LM) coronary artery disease (stenosis >50%)
In the investigator's opinion patient has a co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
Planned surgery within 6 months after index procedure
Life expectancy less than 1 year
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rohit Chand, BS
Phone
+91 9909409606
Email
rohitchand@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick W Serruys, PhD
Organizational Affiliation
Erasmus MC Thoraxcentrum, The Netherlands
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Hydroxyapatite Active Pro Healing Clinical Trial Program
We'll reach out to this number within 24 hrs